APA

Yanaba K., Umezawa Y., Sakakihara R., Chiba M., Ito T., Kikuchi S., Fukuchi O., Asahina A., Saeki H. & Nakagawa H. (20160824). Infliximab and adalimumab, unlike ustekinumab, increase serum KL-6 levels in Japanese patients with psoriasis. : The Journal of dermatology.

Chicago

Yanaba Koichi, Umezawa Yoshinori, Sakakihara Reiko, Chiba Miki, Ito Toshihiro, Kikuchi Sota, Fukuchi Osamu, Asahina Akihiko, Saeki Hidehisa and Nakagawa Hidemi. 20160824. Infliximab and adalimumab, unlike ustekinumab, increase serum KL-6 levels in Japanese patients with psoriasis. : The Journal of dermatology.

Harvard

Yanaba K., Umezawa Y., Sakakihara R., Chiba M., Ito T., Kikuchi S., Fukuchi O., Asahina A., Saeki H. and Nakagawa H. (20160824). Infliximab and adalimumab, unlike ustekinumab, increase serum KL-6 levels in Japanese patients with psoriasis. : The Journal of dermatology.

MLA

Yanaba Koichi, Umezawa Yoshinori, Sakakihara Reiko, Chiba Miki, Ito Toshihiro, Kikuchi Sota, Fukuchi Osamu, Asahina Akihiko, Saeki Hidehisa and Nakagawa Hidemi. Infliximab and adalimumab, unlike ustekinumab, increase serum KL-6 levels in Japanese patients with psoriasis. : The Journal of dermatology. 20160824.